Case report

COVID-19 and papular manifestations pattern in 3 patients: a retrospective case series

Hossein Sheibani1-*, Elham Azmoodeh2, Amirhessam Kheirieh2 and Khadijeh Aerab Sheibani3

1 Assistant Professor of Cardiology, Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Sciences, Shahroud, Iran
2 Student Research Committee, School of Medicine, Shahroud University of Medical Science, Shahroud, Iran
3 Assistant Professor, Department of Psychology, Payame Noor University, Tehran, Iran

* Correspondence: Email: h1a1sheyban@gmail.com, sheybani@shmu.ac.ir; +982332342000.

Abstract: COVID-19 can be associated with varying degrees of cutaneous lesions. Although these manifestations were rare, they can be considered as a specific symptom of COVID-19. Here, we present 3 patients for whom the diagnosis of COVID-19 was made by RT-PCR and a few days after the onset of systemic symptoms, papular cutaneous lesions appeared and on average after 6 days, the lesions started to disappear without any specific treatments. Demographic and clinical features of the 3 patients are summarized in Table 1.

Keywords: COVID-19; skin manifestations; coronavirus; virus diseases; SARS-CoV-2

Abbreviations: COVID-19: Coronavirus disease 2019; SARS: Severe acute respiratory syndrome; MERS: Middle east respiratory syndrome; WHO: World Health Organization; RT-PCR: Reverse transcription polymerase chain reaction; PMN: Polymorphonuclear leukocytes; SARS-COV-2: Severe acute respiratory syndrome coronavirus 2

1. Introduction

In December 2019, a new virus from the coronavirus family, similar to severe acute respiratory syndrome-related coronavirus (SARS-CoV) and Middle East respiratory syndrome–related coronavirus (MERS-CoV), caused new cases of pneumonia in Wuhan, China [1,2]. According to the
World Health Organization (WHO), the disease was named COVID-19 on March 11 and was declared a global emergency. According to the WHO reports, from the beginning of the disease until December 21, 2020, more than 75,700,000 cases have been diagnosed globally, which indicates rapid spread of the disease [3].

Although COVID-19 affects the respiratory system and main clinical manifestations of the infection present in the upper and lower respiratory system, cutaneous manifestations have been reported in some case series [4,5]. These manifestations can be in the form of morbilliform or urticarial mimicking viral exanthema, papulovesicular, maculopapular and erythematous lesions, or less commonly varicella-like vesicles [4,6,7,8].

Here, we present 3 patients with COVID-19 who developed papular cutaneous manifestation which disappeared without specific treatment.

2. Case presentation

From May 2020 to October 2020, three patients without previous history of any specific illness or recent drug use leading to drug interactions, were admitted to our hospital with suspected symptoms of COVID-19. Demographic and clinical features of the 3 patients are summarized in Table 1. All of them were men (n = 3) and the median age was 35.3 years (range, 33–39 years). All patients had fever, dry cough and mild to moderate dyspnea. Also 66% (n = 2) had body ache. Considering COVID-19 outbreak in the area, reverse transcription polymerase chain reaction (RT-PCR) test for coronavirus on nasopharyngeal specimen was done which was positive for all three patients. Their chest CT-scan revealed bilateral ground-glass opacity features which compatible with COVID-19.

For all the patients, Hydroxychloroquine, Azithromycin, Naproxen and Vitamin D were administered. On average after 11 days (range, 3–17 days), diffuse small to moderate-sized cutaneous lesions were developed on trunk (100%, n = 3), back (66%, n = 2) and upper limbs (66%, n = 2) in the form of reddish papular lesions without secretions (Figures 1–3). No mucosal involvement was found in examination. Moderate itching was reported in 33% of patients (n = 1). As the lesions began to disappear in one anatomic area, they began to appear in another area. On average after 6 days (range 5–8), the lesions started to disappear without any specific treatments. At first the lesions became dark and then disappeared. Lesional biopsy performed on one of the patients (patient’s ID:3) and revealed infiltration of PMNs in epidermis, mild hyperkeratosis and acanthosis (Figure 4).

Table 1. Demographic and clinical features of the patients.

| ID | Sex | Age | Skin Lesions | Skin Symptoms | Localization | Latency time (days) | Duration (days) | Systemic Symptoms |
|----|-----|-----|--------------|---------------|--------------|-------------------|----------------|------------------|
| 1  | M   | 34  | papular      | Itching       | Trunk, Back, Upper limbs | 3                | 8               | Fever, Cough, Dyspnea, Body ache |
| 2  | M   | 33  | papular      | No itching    | Trunk, Back             | 17               | 5               | Fever, Cough, Dyspnea, Body ache |
| 3  | M   | 39  | papular      | No itching    | Trunk, Back, Upper limbs | 15               | 5               | Fever, Cough, Dyspnea         |
Figure 1. Patient’s ID:1 Cutaneous manifestations on upper limbs and dark lesions remaining after recovery.

Figure 2. Patient’s ID:2 Cutaneous manifestations on trunk and dark lesion remaining after recovery on his back.

Figure 3. Patient’s ID:3 Cutaneous manifestations on trunk, upper limbs and back. dark lesion remaining after recovery on back.
Figure 4. Lesional biopsy performed and histological evaluation revealed infiltration of PMSs in epidermis, mild hyperkeratosis and acanthosis.

3. Discussion

COVID-19 after its widespread outbreak in Wuhan, China, has spread rapidly across Asia and entire the world, becoming a health challenge and concern for the global medical system. Initially, the range of symptoms was limited to a viral respiratory infection such as dry cough, low-grade fever, and headache; But over time, newer symptoms of the disease have been seen and reported in other organs of the body, including loss of smell and taste, diarrhea and body aches, and etc [2,9]. Also, recent studies which have investigated clinical features of COVID-19 have shown that this infection can be associated with a range of cutaneous manifestations like maculopapular, papulovesicular, pityriasis rosea-like, urticarial, gangrene, pseudopeniosis, livedo reticularis pustular lesions In a Meta-Analysis by Sameni et al. [10] which reviewed 43 studies, the incidence of such cases was 0.2% in Asian studies especially in China and Thailand. Based on their study, the most common types of cutaneous manifestations were erythematous lesions, rash, and urticarial and also, out of 48 patients with skin manifestations, 4 have papular lesions.

According to studies, the involved region are different in patients and can be the abdomen, limbs and even in a few cases the head and face but in most articles it is stated that the main involved region was the abdomen [4,5,6,7,8]. As we have claimed, there is no report in existing studies on association of skin manifestations with the prognosis or severity of infection by SARS-COV-2.

4. Conclusions

Considering the presented cases and other similar reports in the literature, cutaneous manifestations could be observed in COVID-19 disease, so it is necessary for physicians and healthcare providers to be aware of cutaneous manifestations of COVID-19 disease. Also, special attention should be paid to skin examinations of patients and if they notice skin manifestations, differentiate them from other viral or dermatological disease and drug reactions with symptoms related to COVID-19 disease.

Our only limitation was missing histopathological biopsy from skin lesions of other patients and unfortunately only one patient agreed to a biopsy of his lesions. Therefore, we recommend that
physicians and healthcare providers persuade and reassure patients similar to us to have a biopsy to reveal more details of this manifestation.

Acknowledgements

The authors are grateful to all staff of the Deputy of Health at Imam Hossein Hospital of Shahroud for their great cooperation. The present study with a project code (9948) was approved by the Ethics Council of Shahroud University of Medical Sciences (IR.SHMU.REC.1399.056). For the patient consent form, we obtained their written consent and all three of them signed and approved the relevant form.

Conflict of interests

The authors declares that there is no conflict of interest in this paper.

References

1. Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395: 497–506.
2. Zhu N, Zhang D, Wang W, et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 382: 727–733.
3. World Health Organization (2020) Weekly operational update on COVID-19—21 December 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/wou_21-dec_cleared.pdf?sfvrsn=a7575c1f_1&download=true
4. Recalcati S (2020) Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 34: e212–e213.
5. Suchonwanit P, Leerunyakul K, Kositkuljorn C (2020) Cutaneous manifestations in COVID-19: lessons learned from current evidence. *J Am Acad Dermatol* 83: e57–e60.
6. Hoenig LJ, Pereira FA (2020) Eruption as a clinical manifestation of COVID-19: photographs of a patient. *Clin Dermatol* 38: 502–505.
7. Kaya G, Kaya A, Saurat JH (2020) Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature. *Dermatopathology* 7: 3–16.
8. Marzano AV, Genovese G, Fabbrocini G, et al. (2020) Varicella-like exanthem as a specific COVID-19–associated skin manifestation: multicenter case series of 22 patients. *J Am Acad Dermatol* 83: 280–285.
9. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol* 277: 2251–2261.
10. Sameni F, Hajikhani B, Yaslianifard S, et al. (2020) COVID-19 and skin manifestations: an overview of case reports/case series and meta-analysis of prevalence studies. *Front Med* 7.